Does omalizumab impair glucose homeostasis in a patient with severe persistent asthma and type 2 diabetes mellitus?
Authors:
Open Access
- 30 September 2017
- journal article
- Published by Taylor & Francis in Revista Portuguesa de Pneumologia (English Edition)
- Vol. 23 (5) , 303-304
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectivesEuropean Respiratory Review, 2015
- Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysisScientific Reports, 2015
- Assessment of Pancreatic β-Cell Function: Review of Methods and Clinical ApplicationsCurrent Diabetes Reviews, 2014
- Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellitus: 18 Month follow-upClinical Laboratory, 2014
- Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulationJournal of Allergy and Clinical Immunology, 2013
- Gatifloxacin-induced histamine release and hyperglycemia in ratsEuropean Journal of Pharmacology, 2010